In this Issue:
Bevacizumab + XELOX in elderly patients
FOLFOX vs fluorouracil + leucovorin
Cetuximab no added DFS benefit to FOLFOX4…
…but OS benefit with FOLFIRI
Low variability in CT assessment of tumour response
Overcoming anti-EGFR resistance with MEK inhibition
Improved OS with panitumumab + FOLFOX4
Novel treatments needed for BRAF mutants
Impact of KRAS status on treatment patterns
Evidence of KRAS-mutated subclones
Please login below to download this issue (PDF)